
Dr. Masoud Dara, Team Leader of the TB Programme, WHO Europe, and GHDonline moderator
In the fight against multidrug-resistant tuberculosis (MDR-TB) in high-burden areas, program administrators and health workers with limited resources have to get it right when it comes to managing second line drugs (SLD). They are however confronted with many challenges such as lack of resources and difficulties in procurement and supply management (PSM) of SLD; price regulations; or selection of approved manufacturers.
